Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Asia Pacific

Set Alert for Asia Pacific

China Grants First mRNA COVID Vaccine Approval To Homegrown Latecomer

CSPC Pharmaceutical's SYS6006 has gained an emergency use authorization in China less than one year after entering clinical trials, becoming the first mRNA vaccine for COVID-19 to be approved in the country.

China Vaccines

Australia To Seek Stakeholder Input On Terms Of HTA Review

The review of the health technology assessment system will look at the use of adaptable and flexible approaches to managing future health care technologies, early and equitable access for patients, as well as the possibility of international work-sharing initiatives and comparisons of purchasing practices.

Australia Health Technology Assessment

Japan Price Revision: Mixture of Cuts And Increases Amid Supply Crisis

Japan’s annual drug reimbursement price revision for 2023 will cut approximately $2.3bn from national healthcare costs, and while several temporary price increases have been granted to cope with an ongoing supply crisis for some products, a system of one-off revisions for big sellers remains.

Japan Pricing Debate

Amid US Cough Syrup Findings, Regulators Feel India Needs To Work On Perceptions But Also Make Improvements

In wake of the furore caused by OTC cough syrups made by two small Indian companies, former and current US FDA and MHRA officials say quality-related issues are not specific to India. However, while image management needs some work, manufacturers in the country also need to make further improvements to ensure quality.

Regulation Quality

China’s CDE Explains Major Issues Around Conditional Approval Scheme

China's conditional approval system, which is an accelerated pathway, is being increasingly used by pharma firms, but some thorny issues remain such as the impact on full approvals, the scheme’s relation to priority reviews and currently available therapies and deadlines for confirmatory studies. Staff from the country's Center for Drug Evaluation discussed various topics around the system in a recent article.

China Approvals

Korea’s Biopharma Regulatory Reform Push To Focus On Innovation, Streamlining

South Korea is aiming to implement a broad range of regulatory reform steps to better compete with global rivals and speed up patient access to novel therapies.

South Korea Digital Health

China New Government Policies Taking Shape As Two Sessions Underway

Moderate growth goal and lingering impact from COVID policies dampen prospects of a quick recovery for China.

Policy China

Feedback Sought On Proposals To Improve Australia’s Recall Processes

The deadline is nearing for comments on changes the Therapeutic Goods Administration has proposed making to its therapeutic products recall processes.

Recalls Australia

Global Pharma Guidance Tracker – February 2023

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Guidance Documents Regulation

China Business Pessimism Grows Amid COVID Origin Assessment, Congressional Hearing

Simmering US-China tensions dash hopes that a recent border reopening will put many collaborations back on track, even as more than half foreign businesses now downgrade the importance of investing in China.

Regulation Risk Management

China's Gene-Editing Baby Scientist Stirs Up Rare Disease Controversy

Jiankui He, the researcher behind China's world-shocking gene-edited babies scandal, now leaps into rare diseases research area but ethics oversight remain murky.

Gene Therapy Rare Diseases

Go Global Or Stay Home? Geopolitics, Funding Crunch May Force China Biotechs To Choose

Having been used to navigating the Pacific with few obstacles, biotech companies taking advantage of Chinese resources and US innovation now face ballooning tensions between the two countries, which along with narrowing funding channels will increasingly force them to decide where to place their bets in the world’s largest economies.

China Business Strategies
See All
UsernamePublicRestriction

Register